# EDGAR Filing Document

**Accession Number:** 0001660334
**File Stem:** 0001193125-26-219912
**Filing Date:** 2026-5
**Character Count:** 20473
**Document Hash:** 84a52ffcb54970572bf3efce126e4f5e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-219912.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0001193125-26-219912

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260512

**DATE AS OF CHANGE**: 20260512

**EFFECTIVENESS DATE**: 20260512

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verrica Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001660334
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463137900
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295816
- **FILM NUMBER:** 26970040

**BUSINESS ADDRESS:**
- **STREET 1:** 44 WEST GAY STREET
- **STREET 2:** SUITE 400
- **CITY:** WEST CHESTER
- **STATE:** PA
- **BUSINESS PHONE:** 484-453-3300

**MAIL ADDRESS:**
- **STREET 1:** 44 WEST GAY STREET
- **STREET 2:** SUITE 400
- **CITY:** WEST CHESTER
- **STATE:** PA

**As filed with the Securities and Exchange Commission on May 12, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Verrica Pharmaceuticals Inc.
**(Exact name of Registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **44 West Gay Street, Suite 400**<br> **West Chester, PA 19380** | **46-3137900** |
| **(State or other jurisdiction of<br>Incorporation or organization)** | **(Address of principal executive offices)<br>(Zip code)** | **(I.R.S. Employer<br>Identification No.)** |

---

**2018 Equity Incentive Plan** 

**(Full title of the plan)** 

**Jayson Rieger** 

**President and Chief Executive Officer** 

**Verrica Pharmaceuticals Inc.** 

**44 West Gay Street, Suite 400** 

**West Chester, PA 19380** 

**(Name and address of agent for service)** 

**(484) 453-3300**

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Mark Ballantyne** 

**Divakar Gupta** 

**Cooley LLP** 

**11951 Freedom Drive** 

**Reston, VA 20190-5640** 

**(703) 456-8000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

Pursuant to General Instruction E of Form S-8, Verrica Pharmaceuticals Inc. (the "Registrant") is filing this Registration Statement with the Securities and Exchange Commission (the "Commission") to register 687,151 additional shares of Common Stock under the 2018 Equity Incentive Plan (the "2018 Plan"), pursuant to the provisions of the 2018 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan on January 1, 2026.

In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

**PART II** 

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF DOCUMENTS BY REFERENCE**  |

---

The contents of the earlier registration statement related to the 2018 Plan, previously filed with the Commission on July 13, 2018 ([<u>File No.</u> <u>333-226153</u>](http://www.sec.gov/Archives/edgar/data/1660334/000119312518217347/d394291ds8.htm)) are incorporated herein by reference and made a part of this Registration Statement.

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS**  |

---

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 4.1(1) | [Amended and Restated Certificate of Incorporation of the Registrant.](http://www.sec.gov/Archives/edgar/data/1660334/000119312518170726/d361077dex33.htm) |
| 4.2(2) | [Certificate of Amendment of the Amended and Restated Certificate of Incorporation.](http://www.sec.gov/Archives/edgar/data/1660334/000119312525162939/d30630dex31.htm) |
| 4.3(3) | [Amended and Restated Bylaws of the Registrant.](http://www.sec.gov/Archives/edgar/data/1660334/000119312518170726/d361077dex34.htm) |
| 4.4(4) | [2018 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1660334/000119312518183862/d361077dex104.htm) |
| 4.5(5) | [Form of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2018 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1660334/000119312518183862/d361077dex105.htm) |
| 5.1 | [Opinion of Cooley LLP.](d135825dex51.htm) |
| 23.1 | [Consent of KPMG LLP, Independent Registered Public Accounting Firm.](d135825dex231.htm) |
| 23.2 | [Consent of Cooley LLP (included in Exhibit 5.1).](d135825dex51.htm) |
| 24.1 | [Power of Attorney (included on the signature page of this Form S-8).](#tx135825_sig) |
| 107 | [Filing Fee Table](d135825dexfilingfees.htm) |

---

(1) Previously filed as Exhibit 3.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Commission on May 22, 2018, and incorporated by reference herein.

(2) Previously filed as Exhibit 3.1 to the Company's Current Report on Form 8-K (File
No. 001-38529), filed with the Securities and Exchange Commission on July 23, 2025.

(3) Previously filed as Exhibit 3.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Commission on May 22, 2018, and incorporated by reference herein.

(4) Previously filed as Exhibit 10.4 to Amendment No. 1 to the Registrant's Registration Statement on
Form S-1 (File No. 333-225104), filed with the Commission on June 5, 2018, and incorporated by reference herein.

(5) Previously filed as Exhibit 10.5 to Amendment No. 1 to the Registrant's Registration Statement on
Form S-1 (File No. 333-225104), filed with the Commission on June 5, 2018, and incorporated by reference herein.

---

| | |
|:---|:---|
| **ITEM 9.** | **UNDERTAKINGS**  |

---

**1**. The undersigned registrant hereby undertakes:

**(a)** To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

**(i)** To include any prospectus required by Section 10(a)(3) of the Securities Act;

------

**(ii)** To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.

**(iii)** To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

*Provided, however*, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

**(b)** That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

**(c)** To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

**2**. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section
15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.

**3.** Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of West Chester, Commonwealth of Pennsylvania, on this 12th day of May, 2026.

---

| | |
|:---|:---|
|  VERRICA PHARMACEUTICALS INC. | VERRICA PHARMACEUTICALS INC. |
| By: | /s/ Jayson Rieger |
|  | Jayson Rieger |
|  | *President and Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jayson Rieger, John J. Kirby and David Zawitz, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

------

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jayson Rieger<br> Jayson Rieger | President, Chief Executive Officer and Director<br> *(Principal Executive Officer)* | May 12, 2026 |
| /s/ John J. Kirby<br> John J. Kirby | Interim Chief Financial Officer<br> (*Interim Principal Financial Officer and <br>Interim Principal Accounting Officer*) | May 12, 2026 |
| /s/ Paul B. Manning<br> Paul B. Manning | Director | May 12, 2026 |
| /s/ Sean Stalfort<br> Sean Stalfort | Director | May 12, 2026 |
| /s/ Gavin Corcoran<br> Gavin Corcoran | Director | May 12, 2026 |
| /s/ Mark Prygocki<br> Mark Prygocki | Director | May 12, 2026 |
| /s/ Lawrence Eichenfield<br> Lawrence Eichenfield | Director | May 12, 2026 |
| /s/ Diem Nguyen<br> Diem Nguyen | Director | May 12, 2026 |
| /s/ Charles Frantzreb<br> Charles Frantzreb | Director | May 12, 2026 |
| /s/ Charles Frantzreb<br> Charles Frantzreb | Director | May 12, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g135825g0508233224498.jpg)

Mark Ballantyne

T: +1 703 456 8084

mballantyne@cooley.com

May 12, 2026

Verrica Pharmaceuticals Inc.

44 West Gay Street, Suite 400

West Chester, PA 19380

Ladies and Gentlemen:

We have acted as counsel to Verrica Pharmaceuticals Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 687,151 shares (the "***Shares***") of the Company's Common Stock, par value $0.0001 per share, pursuant to the Company's 2018 Equity Incentive Plan (the "***2018 Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectus, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the 2018 Plan, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion herein is expressed solely with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the 2018 Plan, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This letter speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

---

| | |
|:---|:---|
|  Sincerely, | Sincerely, |
| COOLEY LLP | COOLEY LLP |
|  By: | /s/ Mark Ballantyne |
|  | Mark Ballantyne |

---

RESTON TOWN CENTER, 11951 FREEDOM DRIVE, RESTON, VIRGINIA 20190-5640 T: (703) 456-8000 WWW.COOLEY.COM

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the use of our report dated March 11, 2026, with respect to the financial statements of Verrica Pharmaceuticals Inc., incorporated herein by reference.

/s/ KPMG LLP

Philadelphia, Pennsylvania

May 12, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Verrica Pharmaceuticals Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common stock, $0.0001 par value per share, 2018 Equity Incentive Plan | 457(a) | 687151 | $6.79 | $4665755.29 | 0.0001381 | $644.34 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $4665755.29  |  | $644.34  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $644.34  |

---

 **Offering Note** <br>

<sup>1</sup> Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock of Verrica Pharmaceuticals, Inc. (the "Registrant") that become issuable under the Registrant's 2018 Equity Incentive Plan (the "2018 Plan") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant's common stock, as applicable. The amount registered represents shares of common stock that were added to the shares reserved for future issuance under the 2018 Plan on January 1, 2026, pursuant to an evergreen provision contained in the 2018 Plan. Pursuant to such provision, the number of shares reserved for issuance under the 2018 Plan will automatically increase on January 1 of each year for a period of 10 years, beginning on January 1, 2026 and continuing through (and including) January 1, 2035, in an amount equal to 4% of the total number of shares of the Registrant's common stock outstanding on December 31 of the immediately preceding year, except that, before the date of any such increase, the Registrant's board of directors may determine that the increase for such year will be a lesser number of shares. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price for the shares of common stock being registered under the 2018 Plan are estimated in accordance with Rules 457(c) and 457(h) solely for the purpose of calculating the registration fee are based upon a per share price of $6.79, which is the average of the high and low selling prices per share of the Registrant's common stock on May 5, 2026 as reported on the Nasdaq Capital Market.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---